Enanta Pharmaceuticals remains a Buy as zelicapavir shows promise in RSV trials; strong financials support growth. Read why ENTA stock remains a Buy.
Enanta: Despite Primary Endpoint Miss Zelicapavir Could Benefit From Trial Design Change
Enanta Pharmaceuticals remains a Buy as zelicapavir shows promise in RSV trials; strong financials support growth. Read why ENTA stock remains a Buy.